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Clinical review
Efficacy and safety of antidepressants for children and
adolescents
Jon N Jureidini, Christopher J Doecke, Peter R Mansfield, Michelle M Haby, David B Menkes,
Anne L Tonkin
How safe and effective are antidepressants in children and adolescents? The authors of this review
have found disturbing shortcomings in the methods and reporting of trials of newer antidepressants
in this patient group
Antidepressants introduced since 1990, especially
selective serotonin reuptake inhibitors and venlafax-
ine, have been used increasingly as first line treatment
for depression in children.1 2 The safety of prescribing
antidepressants to children (including adolescents) has
been the subject of increasing concern in the commu-
nity and the medical profession, leading to recommen-
dations against their use from government and
industry (box 1). In this paper, we review the published
literature on the efficacy and safety of newer
antidepressants in children.
Methods
Having criticised the way in which Keller et al
interpreted the results of their study,3 4 we sought to
check the quality of methods and reporting of other
published trials of newer antidepressants in children
(box 2). Of seven published randomised controlled
trials of newer antidepressants for depressed children
published in refereed journals, six used a placebo
control.3 5–9 We analysed each study’s methods and the
extent to which authors’ conclusions were supported
by data. The seventh study, which compared a newer
antidepressant with a tricyclic antidepressant without
finding significant difference,10 was not included in the
analysis but appears in the table on bmj.com.
Funding of trials
Pharmaceutical companies paid for the trials and
otherwise remunerated the authors of at least three of
the four larger studies (table).
Box 1: Warnings about antidepressants in
children
June 2003—Letter from GlaxoSmithKline to all
medical practitioners in the United Kingdom actively
discouraging the use of paroxetine in patients less
than 18 years of age, on the basis of recently disclosed
trial results showing unacceptable risk of serious
adverse effects, including hostility and suicidality.
www.researchprotection.org/risks/PaxilRisks0603.html
(accessed 17 Mar 2004)
June 2003—Warning from the UK Committee on
Safety of Medicines against the use of paroxetine in
children. www.mhra.gov.uk/news/2003/
seroxat10603.pdf (accessed 1 Mar 2004)
August 2003—Warnings about venlafaxine,
promulgated by the manufacturer. www.effexor.com/
pdf/Wyeth_HCP.pdf (accessed 30 Dec 2003)
December 2003—UK Committee on Safety of
Medicines bans all remaining selective serotonin
reuptake inhibitors, except fluoxetine, for use in
patients under 18 years of age. medicines.mhra.gov.uk/
ourwork/monitorsafequalmed/safetymessages/
ssrioverview_101203.pdf (accessed 30 Dec 2003)
March 2004—FDA issues. Public Health Advisory on
cautions for use of antidepressants in adults and
children. www.fda.gov/bbs/topics/ANSWERS/2004/
ANS01283.html (accessed 27 Mar 2004)
Summary points
Investigators’ conclusions on the efficacy of newer
antidepressants in childhood depression have
exaggerated their benefits
Improvement in control groups is strong;
additional benefit from drugs is of doubtful
clinical significance
Adverse effects have been downplayed
Antidepressant drugs cannot confidently be
recommended as a treatment option for
childhood depression
A more critical approach to ensuring the validity
of published data is needed
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Efficacy
The table on bmj.com summarises the trials reviewed.
A total of 477 patients in the six studies were treated
with paroxetine, fluoxetine, sertraline, or venlafaxine
( ≥ 23% dropouts), and 464 were treated with placebo
( ≥ 25% dropouts). Of 42 reported measures, only 14
showed a statistical advantage for an antidepressant.
None of the 10 measures relying on patient reported
or parent reported outcomes showed significant
advantage for an antidepressant, so that claims for
effectiveness were based entirely on ratings by doctors.
No study presented data on rates of attempted self
harm, presentations to emergency or mental health
services, or school attendance.
Two small studies found no statistically significant
advantage for antidepressants over placebo on any of
the outcome measures reported.5 6 Of the remaining
four papers, two did7 9 and two did not3 8 show statisti-
cally significant advantages for antidepressants over
placebo on primary outcome measures.
We meta-analysed the five published studies on
selective serotonin reuptake inhibitors by using the
standardised mean difference (Hedges’ g) as the
measure of effect.3 5 7–9 We averaged relevant outcome
measures within studies and then pooled them across
studies by using a random effects model. We included
all continuous outcome measures related to
depression and health related quality of life. The effect
size was small 0.26 (95% confidence interval 0.13 to
0.40). Assuming a standard deviation of scores of 11 to
14 on the revised children’s depression rating scale
in depressed children, an effect size of 0.26 is equival-
ent to a very modest 3 to 4 point difference on the
scale, which has a range of possible scores from 17 to
113.
As regards unpublished studies, we note from a
report from the US Food and Drug Administration
Center for Drug Evaluation and Research that only
one of nine showed a statistical advantage for drug
over placebo.11
Adverse effects of treatment
Because the follow up period for the randomised con-
trolled trials was short, and numbers were relatively
small, serious adverse effects were likely to be few.
When they do occur, we would therefore expect
authors to draw attention to them, along with data
available from other sources that suggest that serious
adverse effects might occur. Of 93 patients treated with
paroxetine by Keller et al, 11 had serious adverse
events, compared with 2/87 in the placebo group.3 The
authors presented no statistical analysis, but the differ-
ence was significant (Pearson’s 2 = 6.09, df = 1,
P = 0.01). In spite of this striking difference in serious
events between paroxetine and placebo, Keller et al
concluded that, “paroxetine was generally well
tolerated in this adolescent population, and most
adverse effects were not serious,” even though seven
patients were admitted to hospital during treatment
with paroxetine.3 Furthermore, despite five of these
patients being admitted to hospital with events known
to occur with the use of selective serotonin reuptake
inhibitors, including suicidality, only one serious event
(headache) was judged by the treating investigator to
be related to paroxetine treatment. The criteria for
determining causation of serious events were not
stated.
Among 373 patients in the trial by Wagner et al, 9%
(17/189) treated with sertraline withdrew because of
adverse events, compared with 3% (5/184) in the
placebo group.9 These authors also published no
statistical analysis of this outcome or details of the
adverse effects, but the difference in withdrawal rates
was significant (Pearson’s 2 = 6.62, df = 1, P = 0.01).
Wagner et al reported seven adverse effects that
occurred in at least 5% of the sertraline group, at least
twice as often as in the placebo. Despite these results
they concluded that, “sertraline is an effective, safe, and
well tolerated short-term treatment for children and
adolescents.”
Other sources of data support the view that
adverse effects might be more frequent than the
authors of these studies imply. For example, children
and adolescents with obsessive compulsive disorder
exhibit a variety of treatment emergent effects of
fluoxetine, including an “activation syndrome” affect-
ing up to half of young patients; self injurious ideation
or behaviour was seen in 6/42 patients.12 The failure
of drug companies to disclose increased suicidal activ-
Box 2: Search strategies
Medline (1989 to February 2004) and Embase (1988
to 2004 week 04)
(“Depressive Disorder”[MeSH]) AND (“Serotonin
Uptake Inhibitors”[MeSH] OR “Antidepressive
Agents”[MeSH] OR “Antidepressive Agents,
Second-Generation”[MeSH] OR “Antidepressive
Agents, Tricyclic”[MeSH] OR citalopram OR
duloxetine OR escitalopram OR fluoxetine OR
fluvoxamine OR milnacipran OR mirtazapine OR
moclobemide OR nefazodone OR paroxetine OR
reboxetine OR sertraline OR trazodone OR
venlafaxine ) AND (randomized controlled
trial[Publication Type]) AND (“Child”[MeSH] OR
“Adolescent”[MeSH])
PsycLIT (1985 to February week 3 2004)
(exp Serotonin Reuptake Inhibitors/ or exp
Antidepressant Drugs/ or exp Major Depression/ or
exp PAROXETINE/ or exp FLUOXETINE/ or exp
SERTRALINE/ or exp MOCLOBEMIDE/ or exp
FLUVOXAMINE/ or exp CITALOPRAM/ or exp
TRAZADONE/ or exp Imipramine/ or exp
Antidepressant Drugs/ or exp TRICYCLIC
ANTIDEPRESSANT DRUGS/ or exp Desipramine/
or (keywords) venlafaxine or duloxetine or
escitalopram or milnacipran or mirtazapine or
moclobemide or nefazodone or reboxetine) AND exp
CHILD PSYCHIATRY/
Funding sources for trials of antidepressants
Trial Source of funding
Simeon et al (1990)5 Not disclosed
Mandoki et al (1997)6 Not disclosed
Emslie et al (1997)7 Attributed to National Institute of Mental Health, but FDA
data show that study was sponsored by Eli Lilly20
Keller et al (2001)3 GlaxoSmithKline; two authors employees of
GlaxoSmithKline
Emslie et al (2002)8 Eli Lilly; all authors employed by or otherwise
contracted to Eli Lilly
Wagner et al (2003)9 Pfizer; all authors paid by Pfizer; two Pfizer employees;
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High rates of withdrawal occurred in all the studies,
ranging from 17% to 32% for patients treated with
selective serotonin reuptake inhibitors and from 17%
to 46% for placebo treated patients. Such high rates of
withdrawal over relatively short study periods (typically
8-10 weeks) raise concerns about the possible
introduction of bias by the analytical method chosen.
Most of these studies used an intention to treat, last
observation carried forward approach. The last obser-
vation carried forward approach is based on the
assumption (unlikely in childhood depression) that the
condition of patients who have dropped out would
have remained unchanged for the remainder of the
study, had they continued in it. In none of these studies
were the withdrawn patients assessed at the end of the
trial to assess their outcome (a “true” intention to treat
approach). The higher the drop-out rate the more
likely a last observation carried forward approach is to
produce unreliable results.
Use of categorical outcomes
Categorical outcomes (such as response and remis-
sion) are likely to inflate small differences between
groups.14 As categorical outcomes are usually based on
data from continuous measures, the difference in con-
tinuous measures should always be examined first and
given priority. This approach has often not been
followed in the childhood antidepressant literature,
where three of six nominated primary outcome
variables were categories created by dividing continu-
ous measures.
Unblinding
The real proportion of effect attributable to a selective
serotonin reuptake inhibitor may be less than
apparent, given that the placebo versus drug
difference is less where active placebo is used (that is,
placebo with an active pharmacological principle that
produces side effects).15 This finding suggests that part
of the impact of an active drug might be due to
unblinding as a result of detection of side effects by
patients and doctors. No data are given in any paper
reviewed here on the effectiveness of blinding.
Blinding was “essentially” maintained for a subset of
the participants in the Emslie (1997) study.7 16
However, the authors did not examine adverse events
as a possible cause of unblinding, and they noted in
their conclusions that “the role that minimal side
effects for the active medication played undoubtedly
contributes to these findings.” Other work suggests
that clinicians will have performed better than chance
at predicting whether or not their patients were on the
active drug,17 so that unintended bias may be a
contributing or decisive cause of observed differences
between the drug and placebo groups.18
Doubtful clinical implications of statistical
superiority to placebo
Given the large placebo effect in all six studies
reviewed, the clinical significance of the drug effect
should be questioned. For example, in spite of a one
week placebo lead-in and exclusion of initial placebo
responders, Emslie et al (2002) found that, for the
measure showing the greatest advantage of fluoxetine
over placebo (revised children’s depression rating
scale), the improvement in the placebo group was 70%
of the improvement seen in the fluoxetine group (22
point decrease for fluoxetine v 15 points for placebo).8
Similarly, the fact that 87% of the improvement in the
sertraline group was reproduced in the placebo group
casts some doubt on Wagner et al’s claim,9 and Varley’s
editorial support for that claim,19 that their results are
clinically, as well as statistically, significant. This is illus-
trated by the graph from their paper (fig), which shows
that, although they found a significant difference at 10
weeks, it was very small in size and unlikely to be clini-
cally important.
Quality of reporting
In discussing their own data, the authors of all of the
four larger studies have exaggerated the benefits,
downplayed the harms, or both. This raises the
question of whether the journals that published the
research reviewed the studies with a sufficient degree
of scrutiny, given the importance of the subject. Despite
the authors’ initial claims, data reported by Keller et al
showed no statistically significant advantage of drug
over placebo.3 Neither of the two pre-designated
primary outcome measures (change from baseline in
the score on the Hamilton rating scale (depression)
and “response” defined as a fall in score below 8 or by
50%), were significantly different between paroxetine
and placebo. Interpretation of these data was confused
by an unexplained change in the definition of
“response” to “reduction of HAM-D to below 8”. Alter-
ing this definition enabled the authors to claim signifi-
cance on a primary endpoint. The authors have
subsequently modified that claim to having shown a
“signal for efficacy.”20
The two studies ultimately published by Emslie and
colleagues in 1997 and 2002 (B1Y-MC-X065 and B1Y-
MC-HCJE) were the subject of a “statistical review” by


























Weekly and overall adjusted mean scores on revised children’s
depression rating scale. Week 1, P=0.09; week 2, P=0.08; week 3,
P=0.01; week 4, P=0.008; week 6, P=0.37; week 8, P=0.18; week 10,
P=0.001; mean response, P=0.007. Reproduced, with permission,
from JAMA 2003;290:1033-41
Clinical review
881BMJ VOLUME 328 10 APRIL 2004 bmj.com
 on 7 August 2006 bmj.comDownloaded from 
That document showed that the prespecified primary
outcome measure in the first Emslie study was
proportion of completing patients who achieved
recovery. The original definition of recovery in the
study protocol was a score of ≤ 28 on the revised chil-
dren’s depression rating scale (“remission”) and a clini-
cal global impression-improvement score of 1 or 2.
Two things are clear: firstly, this measure did not reach
statistical significance (P = 0.339); secondly, when the
study was published, new primary outcome measures
were used (see table on bmj.com).
The authors chose a reduction from baseline of
≥ 30% on the revised children’s depression rating
scale (shown on post hoc analysis of the first study to
show favourable advantage to fluoxetine21) as the
single primary endpoint for the second study
(B1Y-MC-HCJE).8 However, they found no statistical
difference between fluoxetine and placebo on this
measure. Although Emslie et al did state in the results
section that significance was not reached on
“response,” they did not make it explicit that this
meant a failure to show change on their stated
primary outcome, and they make much more of the
secondary endpoints that did favour fluoxetine.
Whenever the failure to show superiority of fluoxetine
over placebo in achieving 30% reduction from
baseline on the rating scale is reported, mean
improvement and “remission” are given equal weight
in the published paper, implying that one or both of
them was also a primary endpoint. The authors go on
to make an unqualified claim of efficacy, even though
the drug showed no significant advantage over
placebo on the single primary outcome measure. The
independent “statistical review,” on the other hand,
concludes that, “the sponsor did not win on these two
pediatric depression studies based on the protocol
specified endpoint. The evidence for efficacy based on
the pre-specified endpoint is not convincing.”21
No information is given that provides insight into
why the US Food and Drug Administration ultimately
approved fluoxetine for childhood depression. Nor is it
clear why the UK Committee on Safety of Medicines
exempted fluoxetine from its criticisms through
accepting the published versions of these studies, when
it did not do so in relation to sertraline.22
Wagner et al described their work as “two
randomised controlled trials,” but the methods are
identical, and they and we treated them as a single
trial.9 The trials when combined included a large
enough number of participants (364) to have adequate
statistical power to detect small differences between
treatments. Neither trial showed a statistically signifi-
cant advantage for sertraline over placebo in terms of
the primary endpoint, which in this case was change
from baseline in the revised children’s depression
rating scale score.22 Only when the trials were
combined did a statistically significant difference
emerge, although this was very small (about 2.7 points
on a 113 point scale). Furthermore, we question Wag-
ner et al’s inference that because tricyclic antidepres-
sants are no more beneficial than placebo, even a small
advantage for newer antidepressants justifies their use.
The availability of older interventions that are not ben-
eficial should not lower the threshold for accepting a
new intervention, especially given the availability of
more effective psychological treatments with no
known adverse effects.23
Conclusion
The trials consistently found large improvements in
placebo groups, with statistically significant additional
benefits for active drug on some measures only. These
results make a major benefit from newer antidepres-
sants unlikely, but a small benefit remains possible.
Randomised controlled trials usually underestimate
the serious adverse effects of drugs.24 The fact that seri-
ous adverse effects with newer antidepressants are
common enough to be detected in randomised
controlled trials raises serious concerns about their
potential for harm. The magnitude of benefit is
unlikely to be sufficient to justify risking those harms,
so confidently recommending these drugs as a
treatment option, let alone as first line treatment,
would be inappropriate.
We are concerned that biased reporting and
overconfident recommendations in treatment guide-
lines may mislead doctors, patients, and families. Many
will undervalue non-drug treatments that are prob-
ably both safer and more effective. Accurate trial
reports are a foundation of good medical care. It is
vital that authors, reviewers, and editors ensure that
published interpretations of data are more reasonable
and balanced than is the case in the industry
dominated literature on childhood antidepressants.
This is particularly true in the light of the increasing
reliance on online abstracts by doctors who lack the
time or the skills for detailed analysis of complete trial
reports.
We thank Agnes Vitry, Dianne Campbell, and Brita Pekarsky for
helpful comments on the manuscript.
Contributors: JNJ and ALT had the original idea for the work.
JNJ undertook the primary literature review and drafted the
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serotonin reuptake inhibitors: an overview of
regulatory status and CSM advice relating to
major depressive disorder in children and
adolescents
Moncrieff J. Is psychiatry for sale? Maudsley discussion
paper, 2003 (available as booklet from the Institute of
Psychiatry: sarah.smith@iop.kcl.ac.uk)—An
examination of the influence of the pharmaceutical
industry on academic and practical psychiatry
Social Audit (www.socialaudit.org.uk)—Aims to ensure
that organisations of all kinds “properly and
adequately serve the interests and needs of the public,”
and takes a particular interest in antidepressants
Healthy Skepticism (www.healthyskepticism.org)—An
international non-profit organisation that aims to
improve health by reducing harm from misleading
drug promotion
Garland EJ. Facing the evidence: antidepressant
treatment in children and adolescents. CMAJ
2004;170:489-91—A critique of the way drug
companies manage information
Clinical review
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Lesson of the week
Recurrent hypoglycaemia in a diabetic patient as a result
of unexpected renal failure
Malvinder S Parmar
Hypoglycaemia is the most frequent complication of
diabetes, affecting 10% to 25% of diabetic patients at
least once a year and accounting for 3% to 4% of
deaths in those treated with insulin.1 Diabetic renal dis-
ease is a common complication and is the most preva-
lent cause of end stage renal disease in the western
world.2
The kidney plays an important role in glucose
homoeostasis: in addition to metabolising between
30% and 40% of insulin,3 it provides up to 45% of
endogenous glucose through gluconeogenesis during
a prolonged fast.4 In renal failure, it cannot metabolise
insulin or generate glucose, thereby increasing the
risk of hypoglycaemia. Hypoglycaemia affects 67%
of diabetic patients with renal failure, and in almost
half (46%) of patients it is often related to the
medication they are taking.5 I present a case where a
decline in renal function after treatment with
diclofenac resulted in recurrent episodes of hypogly-
caemia, highlighting the importance of monitoring
renal function in a diabetic patient with new onset
hypoglycaemia.
Case report
A 64 year old man with a 15 year history of type 2
diabetes mellitus presented with a third episode of
hypoglycaemia in two weeks. His diabetes was well
controlled with 35 units of insulin a day, and he had
had no hypoglycaemic episodes in the past two years.
He had no history of hypertension, retinopathy, or
nephropathy. He was compliant with his diet, insulin
therapy, and exercise programme. At a regular check
up two months previously, his blood pressure had been
116/70 mmHg and his HbA1c level 0.07 (normal 0.050
to 0.064), with home blood glucose readings of 5.0-8.0
mmol/l during the previous month. The ratio of urine
microalbumin concentration to creatinine concentra-
tion was 2.0 ( < 2.5), and serum creatinine concentra-
tion was 104 mol/l (44-106 mol/l).
He had started to experience low back pain a
month before presentation with his third episode of
hypoglycaemia and saw his family doctor, who
prescribed diclofenac 50 mg twice daily; his back pain
then improved. Two weeks later, he started to
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group,4 but another study showed that virtual groups
may be less effective than face to face groups to sustain
weight loss.13 In terms of the outcome measures used,
future studies should also include measures of
resource use, as it is currently not clear whether
participation in a peer to peer group reduces or
increases the use of health care.
Given the abundance of unmoderated peer to peer
groups on the internet, researchers must focus their
efforts not only on sophisticated professionally led sys-
tems, but shift their attention to consumer led, self help
venues. Perhaps in this way the research community
can best help consumers to help themselves, a guiding
principle of support groups regardless of the venue in
which they occur.
Contributors: See bmj.com.
Competing interests: None declared.
Note about process: While GE has the same departmental affili-
ation and works (with AS and CR) in the same centre as Alejan-
dro Jadad, guest editor of this theme issue, it was submitted to
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the decision making over this paper, nor was he involved in con-
ception or conduct of this study.
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What is already known on this topic
Thousands of electronic health related peer to
peer support groups in the form of mailing lists,
chat rooms and discussion forums are available on
the internet
Anecdotal evidence shows that electronic peer to
peer self help groups might be beneficial
interventions, although some also warn of the
dangers of such groups
To our knowledge, no systematic synthesis of the
effects of peer to peer support groups has been
conducted to date
What this study adds
Numerous controlled studies with peer to peer
components have been conducted, but only a few
evaluated the effect of peer to peer groups alone
Most studies failed to show an effect, or effects
were confounded by potential effects of
co-interventions
Quantitative studies with factorial design or
evaluating pure peer to peer interventions are
needed to provide robust evidence on the effects
of peer to peer support groups
Corrections and clarifications
Recurrent hypoglycaemia in a diabetic patient as a result
of unexpected renal failure
In this Lesson of the Week by Malvinder S Parmar
(10 April, pp 883-4), the first sentence of the final
paragraph should read: “In chronic, progressive
renal failure the physician is aware of the risk of
hypoglycaemia and adjusts the dose of insulin or
hypoglycaemic agents accordingly.”
Poor more likely to smoke and less likely to quit
In this News Extra article on bmj.com by Roger
Dobson (17 April) we reported on a study
published in the Journal of Public Health. A reader
wondered if this was a mistake and whether the
journal was not in fact the Journal of Public Health
Medicine. The Journal of Public Health Medicine
seems to have changed its name, however, from the
March 2004 issue—to the Journal of Public Health.
The correct reference to the news article is the
Journal of Public Health (2004;26(1)13-8).
Efficacy and safety of antidepressants for children and
adolescents
When the references were renumbered to take
account of a new reference in this clinical review by
Jon N Jureidini and colleagues (10 April 2004, pp
879-83), a reference in the table escaped our
notice. The reference for the FDA (Food and Drug
Administration) data on funding of trials should be
numbered 21 (not 20, as published).
Primary care
1170 BMJ VOLUME 328 15 MAY 2004 bmj.com
 on 7 August 2006 bmj.comDownloaded from 
